GZ IMPROVE MEDICAL INSTRUMENTS CO.

Chart & Performance

D1W1MN

P/E

—

P/S

3.05

EPS

—

Div Yield, %

—

Shrs. gr., 5y

0.33%

Rev. gr., 5y

3.23%

Revenues

645m

-9.31%

Net income

-63m

CFO

80m

+88.11%

Dividend

Jul 06, 20220.04 CNY/sh

Profile

Improve Medical Instruments Co., Ltd. provides technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. Its principal products include IMPROVACUTER evacuated blood collection systems, IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transportation systems, IMPRONURSE infusion pumps and syringe pumps, LONGX urine analysis systems, in-vitro diagnostic reagents, etc. The company also provides blood collection needles, pulsewave blood pressure monitors, thrombosis viscoelastic analysis systems, feces analysis systems, blood collection tube preparation systems, graphic user interface devices, intelligent sorters, multi-function blood collection tables, intelligent queue systems, urine collection tube preparation systems, automatic tube packer systems, and consumable labels. The company was formerly known as Guangzhou Improve Medical Instruments Co., Ltd. Improve Medical Instruments Co., Ltd. was founded in 1996 and is headquartered in Guangzhou, China.

URL

https://www.improve-medical.com/

IPO date

Dec 25, 2009

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	644,621 -9.31%	710,768 -11.14%
Cost of revenue	609,270	654,900
Unusual Expense (Income)
NOPBT	35,352	55,869
NOPBT Margin	5.48%	7.86%
Operating Taxes	17,158
Tax Rate	48.54%
NOPAT	18,194	55,869
Net income	(63,204)
Dividends	(15,938)	(12,367)
Dividend yield	0.65%	0.58%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	353,789	394,235
Long-term debt	16,992	38,618
Deferred revenue	36,516	58,649
Other long-term liabilities	6,133	4,001
Net debt	(96,350)	(52,335)
Cash flow
Cash from operating activities	79,905	42,478
CAPEX	(43,702)
Cash from investing activities	(38,504)
Cash from financing activities	(50,092)
FCF	123,020	106,521
Balance
Cash	237,714	224,046
Long term investments	229,417	261,143
Excess cash	434,900	449,651
Stockholders' equity	315,542	426,139
Invested Capital	854,723	875,274
ROIC	2.10%	6.04%
ROCE	3.01%	4.28%
EV
Common stock shares outstanding	316,019	309,187
Price	7.75 12.48%	6.89 -34.94%
Market cap	2,449,149 14.97%	2,130,301 -34.94%
EV	2,392,044	2,114,228
EBITDA	84,009	102,619
EV/EBITDA	28.47	20.60
Interest	16,564	19,699
Interest/NOPBT	46.86%	35.26%